TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06853184: Study Evaluating the Efficacy and Safety of Artesunate

Sponsor: Amivas Inc. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 90 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$352,800

Rescue Site Savings

+$235,200

Unlock Full NCT06853184 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06853184 Rescue Dossier →